The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

Author： Choi Brian   Alberti Dona   Schelman William   Kolesar Jill   Thomas James   Marnocha Rebecca   Eickhoff Jens   Ivy S.   Wilding George   Holen Kyle  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.66, Iss.5, 2010-10, pp. : 973-980

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cytotoxic evaluation of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in peripheral blood lymphocytes of patients with refractory solid tumors using electron paramagnetic resonance

By                      

Experimental and Therapeutic Medicine, Vol. 2, Iss. 1, 2011-01 ,pp. : 119-123

Spandidos Publications

Access to resources Recommend Favorite

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

By Yen Yun   Margolin Kim   Doroshow James   Fishman Mayer   Johnson Bonny   Clairmont Caroline   Sullivan Dan   Sznol Mario  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 331-342

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

By Campone M.   Isambert N.   Bourbouloux E.   Maury S.   Monin-Baroille P.   Berille J.   Fumoleau P.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 689-695

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

By Wakui Hiroshi   Yamamoto Noboru   Nakamichi Shinji   Tamura Yousuke   Nokihara Hiroshi   Yamada Yasuhide   Tamura Tomohide  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 511-516

Springer Publishing Company

Access to resources Recommend Favorite

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation

By Moneta D.   Geroni C.   Valota O.   Grossi P.   de Jonge M.J.A.   Brughera M.   Colajori E.   Ghielmini M.   Sessa C.  

European Journal of Cancer, Vol. 39, Iss. 5, 2003-03 ,pp. : 675-683

Elsevier

Access to resources Recommend Favorite